Zydus Cadila gets USFDA approval for deferasirox tablets

Zydus Cadila has received final approval from FDA to market deferasirox tablets for oral suspension

432
Approved
Picture: Pixabay

Zydus Cadila gets USFDA approval for deferasirox tablets

Zydus Cadila has received final approval from US Food and Drug Administration (FDA) to market deferasirox tablets for oral suspension in the strengths of 125 mg, 250 mg and 500 mg.

Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old.

Also read: FDA approves Dr Reddy’s NDA for migraine drug

Indication of drug

It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old. The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The group now has 289 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.